The likelihood of finding genomic alterations indicating specific or agnostic molecular targets in luminal ABC is low, and the clinical utility of ET resistance markers such as TP53 mutations is yet to be demonstrated[136,139]. Here, TP53 is linked to aneurysmal bone cyst.